Core Viewpoint - Palisade Bio, Inc. is advancing its clinical-stage biopharmaceutical product, PALI-2108, a once-daily oral PDE4 inhibitor prodrug aimed at treating inflammatory and fibrotic diseases, with a focus on targeted delivery to the terminal ileum and colon [2][6]. Group 1: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs to enhance pharmacology, tolerability, and convenience for patients [6]. - The company is committed to transforming established PDE4 biology into safer oral therapies for chronic inflammatory and fibrotic diseases through its differentiated prodrug platform [6]. Group 2: Product Details - PALI-2108 is designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon, activated by local bacterial bioactivation, which minimizes systemic absorption and improves tolerability [5]. - In a Phase 1b trial, PALI-2108 demonstrated a 100% clinical response in the ulcerative colitis (UC) cohort, with no serious adverse events and favorable pharmacokinetics [7]. Group 3: Clinical Development - The company is progressing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, including an extension phase for maintenance of remission [8]. - Early studies are being completed in fibrotic diseases to further assess PALI-2108's safety, pharmacology, and potential therapeutic benefits across inflammatory bowel disease indications [8].

Core Insights - Palisade Bio has appointed Dr. Laurent Peyrin-Biroulet and Dr. David T. Rubin to its Clinical Advisory Board, enhancing its clinical strategy as it advances PALI-2108 towards Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease [1][2] Company Overview - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs aimed at targeted delivery to the terminal ileum and colon [1][10] - The lead program, PALI-2108, is designed for once-daily oral administration and is pharmacologically inactive until it reaches the lower intestine, where it is activated by bacterial enzymes [9][11] Clinical Development - PALI-2108 has shown a 100% clinical response in a Phase 1b trial for ulcerative colitis, with no serious adverse events reported [11] - The company plans to submit an IND for a Phase 2 clinical study in ulcerative colitis in the first half of 2026, focusing on clinical remission and pharmacodynamic biomarkers over a 12-week period [1][12] Advisory Board Expertise - Dr. Peyrin-Biroulet is a leading authority in inflammatory bowel disease, with over 1200 peer-reviewed publications and significant roles in major IBD organizations [4][5] - Dr. Rubin is recognized for his expertise in clinical trial design and has been instrumental in the development of numerous approved IBD therapies [7][8]

Core Insights - Palisade Bio, Inc. is advancing its lead program, PALI-2108, a gut-targeted PDE4 inhibitor for ulcerative colitis, with two abstracts selected for presentation at major IBD conferences in early 2026 [1][3][4] Group 1: Product Development - PALI-2108 is designed for local delivery of PDE4 inhibition specifically to the terminal ileum and colon, minimizing systemic exposure and enhancing therapeutic index [4][7] - The prodrug is activated in the lower intestine, allowing for sustained local exposure and once-daily dosing, which aims to improve tolerability compared to systemic PDE4 inhibitors [4][7] - In a Phase 1b trial, PALI-2108 achieved a 100% clinical response in the ulcerative colitis cohort, with no serious adverse events reported [7] Group 2: Clinical Engagement - The Crohn's & Colitis Congress 2026 will feature a poster presentation on PALI-2108's ability to restore immune-epithelial balance in ulcerative colitis [2] - The 21st Congress of ECCO will also showcase findings from a Phase 1a study demonstrating clinical, histologic, and biomarker improvements with PALI-2108 [3] - The company aims to engage with the global IBD community to discuss these findings and the potential of PALI-2108 [3] Group 3: Future Plans - Palisade Bio is preparing to initiate a Phase 2 clinical study in ulcerative colitis, focusing on clinical remission and pharmacodynamic biomarkers over a 12-week period [8] - The company is also planning studies in fibrostenotic Crohn's Disease to further evaluate PALI-2108's safety and therapeutic benefits [8]

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and c ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and c ...

Market Performance - U.S. stocks experienced gains, with the Dow Jones index increasing by 1.66% to 49,183.51, the NASDAQ rising by 0.80% to 23,420.85, and the S&P 500 up by 0.81% to 6,913.76 [1] - European shares also saw positive movement, with the eurozone's STOXX 600 gaining 0.94%, Spain's IBEX 35 Index rising by 0.70%, London's FTSE 100 up by 0.54%, Germany's DAX increasing by 1.34%, and France's CAC 40 climbing by 0.20% [5] - Asian markets closed mostly higher, highlighted by Japan's Nikkei 225 gaining 2.97% and China's Shanghai Composite surging 1.38%, while India's BSE Sensex fell by 0.38% [6] Commodity Prices - In commodity trading, oil prices increased by 1.7% to $58.30, gold rose by 2.9% to $4,454.40, silver surged by 7.3% to $76.230, and copper climbed by 5.1% to $5.9815 [4] Company Developments - Momentus Inc (NASDAQ:MNTS) shares surged by 57% to $8.98 following the announcement of an additive-manufactured fuel tank for flight testing [8] - GH Research PLC (NASDAQ:GHRS) shares increased by 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application for GH001 [8] - VerifyMe Inc (NASDAQ:VRME) shares rose by 66% to $1.12 due to a strategic merger letter of intent with Open World [8] - Zenas Biopharma Inc (NASDAQ:ZBIO) shares dropped by 57% to $14.94 after announcing results from the Phase 3 INDIGO trial [8] - Palisade Bio Inc (NASDAQ:PALI) shares fell by 16% to $2.10, and Palvella Therapeutics Inc (NASDAQ:PVLA) decreased by 14% to $86.16 [8] Economic Indicators - The ISM manufacturing PMI declined for the third consecutive month to 47.9 in December, marking the lowest reading since October 2024, down from 48.2 in November and below market estimates of 48.3 [2][7]

Core Viewpoint - Palisade Bio, Inc. is advancing PALI-2108, a novel PDE4 inhibitor targeting ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD), addressing significant unmet medical needs in these conditions [1][3] Intellectual Property - The Japan Patent Office has granted a key patent for PALI-2108, providing composition-of-matter protection until 2041, with potential extensions based on regulatory review timelines [2] - This patent strengthens Palisade Bio's global intellectual property portfolio, supporting the development of PALI-2108 and its broader platform of locally activated PDE4 inhibitor prodrugs [2][3] Clinical Development - PALI-2108 has completed Phase 1a studies and is currently in a Phase 1b cohort study for both UC and FSCD, with Phase 2 IND submissions planned for the first half of 2026 [1][3][6] - In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, demonstrating favorable tolerability and pharmacokinetics [6] Mechanism and Design - PALI-2108 is designed for local delivery of PDE4 inhibition specifically to the terminal ileum and colon, minimizing systemic exposure and enhancing therapeutic index [4] - The prodrug is activated by gut microbiota, ensuring targeted release at the site of inflammation and fibrosis, which aims to improve anti-inflammatory and anti-fibrotic effects while reducing common side effects associated with systemic PDE4 inhibitors [4][6] Future Plans - The company is preparing to initiate a Phase 2 clinical study in UC to evaluate clinical remission and pharmacodynamic biomarkers over 12 weeks, with an extension phase for maintenance of remission [7] - Additionally, studies in FSCD are planned to further characterize the safety and therapeutic benefits of PALI-2108 across inflammatory bowel disease indications [7]

Group 1 - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 100 points on Monday [1] - DigitalBridge Group Inc announced its acquisition by SoftBank Group for an enterprise value of approximately $4.0 billion, resulting in a 9.9% increase in its shares to $15.30 [1] Group 2 - Eightco Holdings Inc shares surged 29.1% to $2.15 following the announcement of a share buyback program for up to $125 million [2] - Palisade Bio Inc saw an 18.6% increase to $2.55 after Piper Sandler initiated coverage with an Overweight rating and a price target of $25 [2] - Regencell Bioscience Holdings Ltd gained 16.3% to $24.60 [2] - Praxis Precision Medicines Inc surged 13% to $304.00 after receiving Breakthrough Therapy Designation from the FDA for ulixacaltamide [2] - Zura Bio Ltd increased by 13% to $5.26 [2] - Precigen Inc rose 8.6% to $4.52 [2] - Autolus Therapeutics PLC jumped 7.8% to $1.80, with Needham analyst raising the price target from $10 to $11 [2] - LightPath Technologies Inc gained 6.6% to $9.62 [2] - NGL Energy Partners LP surged 6.3% to $9.98 [2] - Six Flags Entertainment Corp increased by 5% to $15.64 [2]

Company Updates - Bolt Projects Holdings Inc (NASDAQ:BSLK) announced preliminary fiscal 2025 results and updated its fiscal 2026 guidance, raising its FY2026 sales guidance from $9.000 million to $11.000 million, with fourth-quarter sales projected at $2.700 million [1] - Shares of Bolt Projects Holdings rose 28.2% to $1.73 in pre-market trading following the announcement [1] Market Movements - Republic Power Group Limited (NASDAQ:RPGL) surged 81.4% to $0.4777 in pre-market trading [4] - Fitell Corp (NASDAQ:FTEL) rose 42.3% to $1.04 after announcing an interim dividend and shareholder loyalty program [4] - Antelope Enterprise Holdings Ltd (NASDAQ:AEHL) increased by 38% to $1.78 after a previous decline of 12% [4] - DigitalBridge Group Inc (NYSE:DBRG) gained 36.7% to $19.00 following reports of SoftBank nearing a deal for the company [4] - Davis Commodities Ltd (NASDAQ:DTCK) rose 16.8% to $0.46 after reporting revenue of $95 million for the six months ending June 30, up 42.1% from $66.9 million a year earlier [4] Other Notable Stocks - VolitionRX Ltd (NYSE:VNRX) rose 12.8% to $0.28, with a maintained Buy rating but a lowered price target from $5 to $3 by D. Boral Capital analyst Jason Kolbert [4] - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose 7.1% to $7.54 after submitting a Biologics License Application to the FDA for Imsidolimab [4]

Core Insights - Palisade Bio Inc. (NASDAQ:PALI) has shown strong performance, with a 5.26% increase in stock price to $2.20, marking a four-day winning streak as investors anticipate clinical trial results for its treatment of fibrostenotic Crohn's disease (FSCD) [1][4] - The company plans to present topline results from its Phase 1b study of PALI-2108 in Q1 2026, with an Investigational New Drug submission expected in the first half of the following year [2] - The stock rally is partly attributed to window-dressing activities by institutional investors, who adjust their portfolios before reporting periods [3] Company Performance - Year-to-date, Palisade Bio Inc.'s shares have increased by 33.33% [4] - The company is focused on developing a next-generation oral PDE4 inhibitor prodrug aimed at treating inflammatory and fibrotic diseases [4]